Dexcom products with phones

[podcast src=”” width=”100%” scrolling=”no” class=”podcast-class” frameborder=”0″ placement=”top” primary_content_url=”″ libsyn_item_id=”21745997″ height=”90″ theme=”custom” custom_color=”3e9ccc” player_use_thumbnail=”use_thumbnail” use_download_link=”use_download_link” download_link_text=”Download” /]This week, Dexcom CEO Kevin Sayer spoke to the JP Morgan Healthcare Conference about the G7 and beyond. We talk about information from that presentation and get to as many of your questions as time allows.

This interview took place on Tuesday Jan 11 and much of what we discussed isn’t FDA approved.

Dexcom presentation info here

Club1921 info here 

Our usual disclaimer: Dexcom is a sponsor of this podcast, but they don’t dictate content and they don’t tell me what to ask their executives.

Recent Dexcom episodes:

CTO Jake Leach talks about Garmin, Dexcom One & more

CEO Kevin Sayer talks about G7, Direct to Watch, Adhesive and more

CEO Kevin Sayer talks about Dexcom in Hospital, G7, VA program and more

Check out Stacey’s book: The World’s Worst Diabetes Mom!

Join the Diabetes Connections Facebook Group!

Sign up for our newsletter here


Use this link to get one free download and one free month of Audible, available to Diabetes Connections listeners!

Episode Transcription Below 

Stacey Simms 0:00
Diabetes Connections is brought to you by Dexcom. Take control of your diabetes and live life to the fullest with Dexcom and by Club 1921. Where Diabetes Connections are made
This is Diabetes Connections with Stacey Simms.
Welcome to another week of the show. You know I’m always so glad to have you here. We aim to educate and inspire about diabetes with a focus on people who use insulin. And I’m talking with Dexcom CEO this week, it’s Kevin Sayer, he is back to check in with us again. And in the interest of getting this episode out to you as soon as I could. It might sound a little different right here at the beginning. But Dexcom episodes are always so high interest that it really merits a quick turnaround. I didn’t want to sit on this interview for a week. So here’s the setup. Dexcom CEO Kevin Sayer gave a presentation to the JP Morgan healthcare conference, if you’re listening as this episode goes live, that was just Monday of this week, January 10, the interview you’re about to hear took place on Tuesday, January 11.
My usual disclaimer Dexcom is a sponsor of this podcast, but they don’t dictate content and they don’t tell me what to ask their executives. I asked the Diabetes Connections podcast Facebook group for questions. And Whoa, boy, did you have a lot as always not a surprise. And I really appreciate you sending those in, I got to as many as I could, while also trying to include what the folks at Dexcom had really asked me to bring up there are some topics that they wanted Kevin to make sure to address. And I think we do a pretty good job of trying to reach a balance here.
Kevin, welcome and Happy New Year,

Kevin Sayer 1:46
and Happy New Year to you.

Stacey Simms 1:48
Thank you. Well, this seems to have started out in pretty happy way on the headline, just from this week. Dexcom CEO touts unprecedented performance of G7 in clinical trial. This is after your talk at the annual JP Morgan healthcare conference. Tell me a little bit about that unprecedented performance data.

Kevin Sayer 2:08
I’m happy to. And I just have to qualify it by saying no, I can’t send it to all your listeners at the end of the call yet. We’re still waiting for approval in Europe. And we have filed this with the FDA, I’m going to take you back a little bit, we made a decision when we were going through the G7 development process that we wanted to answer that performed better than G6. And all of our scientists looked at us and they go oh, really, you’re sure because this is really good. And so we spent a lot of time new algorithms and new manufacturing techniques, there’s a lot of things in G7 that make it different. We also wanted to validate that performance with a study that was so large, nobody could refute it. So as you look at the data that I presented at the conference yesterday, over 300 patients 39,000 Match pairs all across since one ranges and on the I CGM standard side, but with the 5% 95% lower bound, and even the absolute points, you can see we are well within all of the iCGM standards, which are very technical and actually are a very good measure of how a sensor actually performs in reality. And they were very thoughtful in developing these standards to try and pick the centers that don’t work to put you statistically in a bind to whereby if you really aren’t performing in the low range or wherever, you’re not going to get that iCGM designation. We’re very comfortably there.
And the overall MARD in the study, Stacey is eight point, you know I it’s in the low eight for adults and pediatrics. And if you start looking at the data, we gather the data sets in three periods, you know, days one and two, the middle days, four, or five and six, and the last days nine and 10. It’s pretty low, I think it’s below 10. In the first group a day, the first days, which are always a little bit higher, traditionally in our centers than the other days. But in those middle and end days, it’s it’s near seven, and strips for six. I mean, we have done something that I’ve been in this business for since 1994. I didn’t think we’d ever do this when I started. As far as being this good. This is really, really good data. And we’re going to continue to deliver the experience to our customers that they demand from us. So as you can as you think about an iCGM that’s driving an automated insulin delivery system. And not only is the performance great, the user where it’s 60% smaller, it’s a 30 minute warm up. It’s a new app. From our perspective, we’ve got a lot of the clarity data, your listeners will know about clarity. We’ve got a lot of your clarity data right on the app. There’s new alarm configurations.

Stacey Simms 4:48
I’m gonna just jump in with a couple of quick clarifications before we go on. You mentioned a number of there that went by quickly I apologize when you talked about the 300 people in this trial 39,000 match what I missed that one

Kevin Sayer 5:00
matched pairs. That’s where you compare the CGM value to the blood glucose value from the laboratory instrument. So the way our studies work is literally we draw blood samples from the individuals in the study at intervals, and then we actually match the CGM data to that laboratory blood instrument. So 39,000 points from these 300 people in this study were matched. Got it?

Stacey Simms 5:27
And you mentioned the MARD mean absolute relative difference. Most of you, as you listen are very familiar with this, the lower the better for CGM G6, I, my understanding was G6 was in the low nines. This is 8.1 for peds. 8.2 for adults, as I’m reading it, that’s right. I know you can’t tell me I’ll ask you anyway, why? What made the difference here? Is it sighs is it algorithm? Do you have anything you can point to? Or is that a trade secret

Kevin Sayer 5:49
it’s combination, I think the algorithm has been the most, the algorithm changes were really extensive here. And, you know, we always have manufacturing processes to get better, the way we build the G7 centers different in every step of the way. Literally, our G6 manufacturing processes go away and the G7 ones take over the summer, we’re a little similar on the actual sensor wire itself, and that manufacturing, but everything else is different. We just think it it’s smaller, it’s a lot shorter than G6 was. And so it is it’s going to be a completely different experience for everybody.

Stacey Simms 6:28
So to go back to what you were talking about, before I jumped in there, you were starting to talk about alarms, is there something different for the alarm,

Kevin Sayer 6:35
the app is different. And so access to them, and, and just how you use them, if we try to get to be more consumer, thoughtful, as we configured the alarms, we’ll see how everybody loves him. It’ll be interesting. The alarms are one of the things we get the most comments on when we launch a product initially, we try and please everyone, but we never please everyone. And then you get you know, the agency at one time. I don’t know if your call. I think one of our other discussions, we had to make the mute override not work on the low end. Boy, we got a lot of people mad at us about that one. So we’ve tried to comply with what our users want, and also comply with what the FDA has asked us to do. But I think users will find the alarm experience. Good as well. I like I think it’s just gonna be a home run. Yeah, well, I

Stacey Simms 7:24
mean, my son would be happy if an alarm never made a noise again. And I know other people who put like it to alarm every time there’s any movement. So I hear where you’re coming from, can you give any insight into the G7 app in terms of what the differences that we may see as users? And I guess especially one of the questions I always get is about follow any changes of significance coming that you can share follows

Kevin Sayer 7:47
on a separate software track. And so the G7 system, the app is just we tried to get more data in the app itself, versus what we have with G6. So a lot of the clarity data, or at least summary query data is sitting there right in your app. And that will be i we think people will like that just to see how they’re doing over time you got your time in range data for, you know, three 714, you know, a month, 90 days, see how you’re doing time in range wise and the app is other than that it’s relatively similar. The startup is different and you know, in the interface is going to be different. I think over time, what you’ll see with us is that app is now going to get more sophisticated, we changed the entire software platform for G7 and started over again, and we developed a software platform, we can now really change and add on to a lot easier than we could in the past. And so we’re hoping to have more frequent software releases.
But we’ve also learned that CGM is not like Battlestar Galactica game, a game where you want to get a new release every two weeks to fire everybody up. We can’t do a release every two weeks, because people depend on this for their, you know, for their lives. And if you do too frequent releases, and you botch a release, you do some wrong, you remember what happened, if we ever make a mistake on the software, the data side, we can’t do that. But we do want to add more features more quickly in this platform will enable us to do that. I think one of the things you’ll see going forward on the software side, we really want to automate a lot of the tech support features.
We’ve added some, you know, you can get FAQs right from the app now with respect to your sensor, but there are other things we think we can do tech support wise in the app that will you know, reduce everybody’s burden. Nobody likes making a phone call and nobody likes picking up the phone. And when we have a sensor fail, and we do have sensors fail, it just doesn’t make any sense that you have to call us if we’ve got data on a phone, it’d be much easier. For example, if we could diagnose that failure right on the app and go through a very quick process to why but where you could get one. I can’t give a timeframe when all those things are going to come but the platform is robust enough that over time, we can add features like that. One of the other nice things about G7, since it’s fully disposable, you know, every sensor has its own unique serial number. Whereas with G6, that same transmitters used with three months’ worth of sensors. So it will be, it will be fun to be able to follow things like that and see how the sensors go through the channel where everybody gets attract things of that nature. So what we’re really looking forward to the change in our business that G7 affords us.

Stacey Simms 10:28
As usual, I have listener questions, I’m going to try to not repeat because you’ve been really accessible in the last year, we’ve talked to a couple of folks from Dexcom, besides yourself. So as you listen, if I didn’t get to your question, or if you have a question, good chance, we actually answered it in the last year, year and a half. But given let me ask you about compression lows, because that’s one of the things we had talked about, about testing the G7. Any update on that in these trials, if you lay on it, you know, circulation slows, and you can get a false reading any better with the G7

Kevin Sayer 10:54
part of the clinical study is in the compression, because you’re pretty much sitting in a chair with a needle in your arm drawing blood. So I’m sorry, we can’t really test that we’ll learn more about compression when it gets in the field. My hope is that it isn’t as much but I can’t promise that because I don’t know, we’re not enough people. I think there are ways over time where we can manage compression better, I’m not going to get into all the science on the phone, believe it or not, I do spend a lot of time with the engineers on this specific issue. Because I have it happened to me from time to time too. So I will call them up say Hey, can we do X, Y or Z? And I think there are some some answers, but I can’t give them away because I don’t want to give away the playbook. So let’s let’s just see what we can do overtime on that one.

Stacey Simms 11:42
Okay. All right. But you know, the next clinical trial just have them lean against the side of their bed.

Kevin Sayer 11:46
We will we’ll have to do well. Diffic very scientific.

Stacey Simms 11:50
Another question came up, and I think I’m gonna knock wood. I think we’ve been very lucky on this. It’s about new iOS launches from Apple. And I’ll read the question and it’ll tell you, briefly our experience. This person said Dexcom is part of the Apple Developer Network developers have access to new release such as iOS months before launch, why does Dexcom lag behind Apple iOS launches by months in terms of quote, approved use. And our experience, frankly, is that we have not had any issues Benny and I both have, we just got but as a 13. Plus, we both had very old phones. And we have a latest software and no glitches for us. But that’s not everyone’s experience, can you talk a little bit about that,

Kevin Sayer 12:30
we do get the iOS versions in advance, and we do our best to comply with them, I would I would tell you that it isn’t as simple as it’s made out to be. And the iOS version that’s launched isn’t always exactly what we’ve worked on as they as they make tweaks, not big ones. But you also test for everything that you know about the new iOS versions, and sometimes are things that you don’t know, that are in there that come back and may affect the app later on, which is why we delay a little bit, we try and go through every bit of testing that you can imagine. And I’ll be honest with your users, Apple’s made iOS changes, because of us, we have called up and said, Look, you got to do XY and Z here we have a problem. And they’re very good to work with, they’ve not been difficult at all, you know, when you think about iOS and Android operating system and all the things that they impact. And it’s very hard not to impact somebody adversely when you do a new iOS launch.
And you know, the perfect example with us is the home you’d override journey that I brought up earlier. In the beginning, I believe the only app that can overcome the mute override within iOS is authorized manna in the beginning was Apple’s alarm clock, but other people would go around it with their apps was a medical device, we can’t do a go around, we have to make sure what we do is in compliance and known so they work with us very well to make sure we could do what the FDA wanted with respect to the mute button. And the same thing with Android on that, and that was a very difficult exercise. So if there’s a delay, it’s because we’re taking time to see what might have been put into iOS that would change our app. And it just one more thing that will stop. new operating systems are often designed to minimize power usage to extend battery life. Oftentimes, minimizing power usage affects an app that has to be running continuously. And those are the types of battles that we fight are things that we have to make sure we test as a new iOS minimizes power usage. Just does that turn us off? Does it does that stop Dexcom? And we’ve had, we’ve discovered things of that nature where it could affect our app. So there you go. Long answers. All right.

Stacey Simms 14:44
No, no, that’s great. And you mentioned you’ve asked iOS you’ve asked Apple to make changes. I assume the alarm was one any others that you can share.

Kevin Sayer 14:52
I know that nothing I could share. Nothing major that I like you said they’re very cognizant of the Dexcom community there we are. You know, we’re we’re a very large part of the iOS, you know, we’re pretty, it’s pretty vocal group when it comes to iOS,

Stacey Simms 15:06
pretty vocal group period, the whole community. Alright, we say that with love. So another question came from my group, which was about Sugarmate. This is a, I would describe it as a third party app that uses the Dexcom information. And now the real time API to display and and act on data in its own way, my understanding is that Tandem owns Sugarmate, just from way of background here. And you know, Dexcom owns a little bit of Tandem. So there’s a relationship there. Can you speak a little bit about data sources, but the bottom line question here was using Sugarmate and the situation to ask you, does Dexcom feel like they own the patient data? Or do the patients still own their data, even when going through the Dexcom web API’s, we believe

Kevin Sayer 15:49
the patient’s own their data, not us, let me rephrase that we believe the patient’s control the use of their data, we are the stewards of that data sitting on our servers. And so we have a responsibility to maintain it and to keep it but where that data goes and where that data is used. We do believe, particularly if it’s identified data, that the patient absolutely has complete control over that there’s vector sugar made, it’s interesting, it was not using API’s before it was a like many and non authorized use of the data to display it in a different format that people quite candidly, mess, like better than looking at the Dexcom app. And that’s fine. That’s why we built the live API’s, we made a server change to upgrade our server platform, again, more capacity, more safety, more redundancy. It’s a project that’s been going on for years. And we’ve come to the end of that project this year. And when doing so there were some technical issues with Sugarmate, they very quickly switched over to the live API’s. And now this is an authorized use of the data based on platform and data pipes that we built. So we’re willing to share the data with people when they want it. I think that’s an attitude of Dexcom. That changed very much over the years, when we first started, we had a hard time with that concept. Because we worked so hard to invent this technology and gather this data, why would we share it with anybody and say, See, you remember the early days and Nightscout, they were mad at us, we were mad at that. Now, we’re not mad at anybody anymore. I think it’s important that the data sharing be structured and be used for good purposes. But you know, all in all, it’s a, it’s a good use of the data that we have, because these are still Dexcom customers. If you want to, you’re still buying sensors and using them. It’s not a bad thing.

Stacey Simms 17:35
Let me ask you a question about the sensors. And this came up in the fall. I’ve seen it less since but it’s still out there. And I don’t know if this is something you can answer. But it seems that we have not received this. But it seems that some customers are getting the G6 sensors, the inserters brand new in the original packaging, but a new label on it that says this product meets shelf-life extension requirements. I’m your people I reached out to them in the fall, they told me the stickers, oh, you know, it’s all legit. There are updated expiration dates. But I’m curious why this is happening. And you know, what is the shelf life of the G6,

Kevin Sayer 18:10
I can tell you exactly what’s going on, you do shelf-life testing for product as selling your product will last. And over the course of our product lifecycle, you trying to extend that shelf life through more testing to make sure the product still works for the same amount of time period, if you manufactured product with 12 months shelf life, and then extend that shelf life to 18 months. And it’s still the same product and still same manufacturing process rather than unbox it, put it in a new box or throw it away, we put a sticker on the outside because it’s same products been tested, it’s been proven that it works for 18 months, that’s not a problem. That doesn’t mean that it’s 18 months old, we never have inventory that sits around that long to my knowledge, but we do extend shelf lives, it’s important for us to do that, with respect to the distribution channel, particularly as we go to the pharmacy, you know, in the drugstore and and our distributors, the longer they have, you know that they can keep product, the better. We don’t want people throwing product away if they don’t have to. So all that means is we’ve extended our testing and shown that the product still works for a longer period of time and wanted to to label the product accordingly. That’s all

Stacey Simms 19:17
Yeah, I think because it came at a time when there is nervousness just in general not just in diabetes about supply chain and, you know, scarcity concerns. It just seemed unexpected, if that makes sense.

Kevin Sayer 19:30
Well I one of the reasons to extend life is in fact supply chain we don’t have inventory issues with G6 you know G6 is a very very well running process right now and still, you know, the premier sensor on the market. In fact, we launched a G6 derivation product in Europe, these past three months called Dexcom. One a it’s a cash pay product sold on the E commerce platform in four European countries say See now and it’s a lower price and geographies. But we did a feature that we took away, share and follow. We’re not connecting any devices. It’s it’s a simpler technology. And again, we have d six supply to be able to go and do things like that. And we are planning to have G7 capacity to do similar things. We are not shooting small on either front will have capacity on both sides. And, you know, listeners on a supply chain perspective, we have been extremely diligent with respect to components for our products. And right now we see things very good today. We my operations team has just been outstanding on this front. So knock on wood, no, no Dexcom problems today.

Stacey Simms 20:40
All right, two more questions for you. As always, we’re going to run out of time. And as you’re listening, I would refer you again, we did have a conversation about Dexcom. One in a previous show. So I will link that up. This one is more of I’ve asked this, you answered it, but I still continue to get questions to please ask you please make sure when GS seven comes out that Medicare is taken care of?

Kevin Sayer 21:00
Well, that is a great question. And I think we’ve learned from our mistakes in the past. So we will when we get G7 done, what we will do is we will file with CMS to get G7 reimbursement. That’s a process that I’ve heard anecdotally takes three to six months. So if we can get it done in three months, we can’t file with CMS until it’s approved. But we’ll file after approval, and then we’ll go and it is our plans to have capacity for all of our US users. When we go it is not that Medicare delay for G6 was one of the most emotionally gut-wrenching things I’ve dealt with here, because you can’t imagine how many emails I got. But we didn’t have capacity, and we didn’t have everything ready. We’ve learned from our mistakes. And we’ll hopefully be ready to go to everybody. That’s our plan right now.

Stacey Simms 21:49
That’s great. Okay, and my last question is, and I hate doing this to you, but I’m doing it anyways, look into the chapter, we’re gonna look, we’re gonna come at it sideways, because I did have one listeners and ask him what’s planned for the g8? And I said, Come on, let’s let him get the G7. Oh, you know what? I’m happy? You can answer that. Let’s go for it?

Kevin Sayer 22:07
Well, well, I’ll give you two because we did lose some time in the beginning because my computer wasn’t functioning properly. As we look to the future, we want performance to continue to be better. And then we ask ourselves, but we’re getting to the point where as you get to an eight, Mar D, we’re getting close to finger six, I don’t know how much more of a gap there’s going to be, as we look to the future, and even G7 derivatives, we want to go to a longer life, we want to go to 15 days rather than 10. We’ll be running studies doing that over the next couple of years. We’ve got a couple of plans there. We’re always looking to upgrade the electronics, and how much better electronics, you know, I know one of your bigger user complaints is connectivity and loss of data, how do we improve that experience for our customers to make that better over time? Because we can always be better. And phones change faster than medical devices? So what why do we put there, we’re looking at ways how we can help the environment for future product launches again, and changes in the next platforms, G6 has a lot more materials than G7 does as far as just raw plastic. So how do we make an impact there? On the cost side, there’s some form factor things that are pretty far out there that we look at that I won’t go into that are really, really fun. We’ll see if we had done that. And if they’re feasible from a cost of manufacturing perspective, but again, we’re now very much focused on customer preference, rather than can’t we make this work well enough, you know, in my early days here, it’s Can we can we just get this thing working well enough to whereby people can rely on it. Whereas now it’s one of those features that are going to make it a more engaging experience. And the last one will be software and analytics and things like that, as I look out over time, do we end up with analytics to whereby we can offer our users a menu of choices on the software side to whereby they can get more if you want Dexcom when don’t want to connect or talk to anybody? You can have that if you want something that literally literally analyzes every glucose measurement that you take and does something scientifically. How do you get there, I think there’s a number of experiences we can develop over time for future product generations without changing the form factor. So I don’t see any slowdown in investment on the r&d side. And on the product side, G6 is the best product out there now and G7 will just be better in every way. And then we just keep going from there.

Stacey Simms 24:27
And I appreciate you answering that. Thank you. So if you keep going from there, this is the sideways kind of question I wanted to ask. Okay, go ahead. Okay. A couple of days ago, Abbott announced the idea of what they’re calling Lingo, which is bio wearables that will track not only glucose, but ketones and lactate and alcohol. And they say these are not medical devices. You know, this is for people who want to be you know, ultra-marathoners and things like that. We’re already seeing sensors used in that way right now. Any plans to do something like this?

Kevin Sayer 24:56
You know what our electronics platform for G7 We could put any, if we could develop a sensor wire with membranes and analytes and such for to measure something else, it would fit right into G7. And we design G7. With that in mind, we have advanced technology work going on with the other analytes. But it’s still an advanced technology phase, we have to answer a couple of questions. First, have we done all we’re supposed to do on the glucose side? Before we run there, and we got a lot to do right now, Stacy, you’ve heard me talk on this call. And so we need to get done what we started, we need to get G7 launched, we need to scale it up and manufacture it in the 10s. And ultimately, hundreds of millions of products as we stand up a factory in Malaysia and get our Arizona facility built out even more. So we’ve got to get that work done. The second piece, I’m going to answer this in three pieces. The second piece is what is the commercial opportunity for each of those things. They did announce this line of sensors, but they’re all individual sensors.
So I’ve worn a lactate sensor, I’ll be completely honest with you from the lab and seeing what it does to my workouts and it’s very cool, I can see which workout is better than another one. But I’m not ultra-marathoner, I probably wouldn’t change my life. But it was very interesting to look at. There are other scientific uses of black data, particularly in a hospital setting. But what is the market for those, and so we’re gonna kind of take an approach, we’ll continue to develop the science and if Abbott wants to go develop a market, I am happy to follow this time rather than create it, like we’ve done with glucose. The third piece of this is there are a lot of biosensors out there. Now, you have your Apple Watch, and Apple is continuing to gather more and more data or ranks, whoop bands, Fitbits, they’re advertised on television all the time, I would love to incorporate data from these other sensing technologies into into Dexcom. And vice versa, share our data with those people, particularly as you head down the health and wellness path. And let’s get some other people’s sensors into our platform. In all honesty, if Abbott’s really good at sensing these other things, we’ll take that data on our platform and analyze it to if they want to, I guarantee you, that probably isn’t gonna, gonna happen. But we would, you know, let’s be open about this. We’re going to get our glucose work done to because we’ve not seen an opportunity that exceeds this.

Stacey Simms 27:13
Got it? Excellent. Well, thank you so much for answering that it really is so interesting to watch and to see if, as you say, if any of this really, really makes a difference commercially, if people do want to adopt it widely. You know, I think the jury’s still out, so we shall follow.

Kevin Sayer 27:26
Hey, thanks for having me again.

Stacey Simms 27:27
Thank you so much. Have a great day.
You’re listening to Diabetes Connections with Stacey Simms.
More information at the episode homepage, diabetes, Dash I’ll have the transcription up as soon as I can. But again, quick turnaround on this episode. Thank you so much, again, for sending in the questions. Obviously, I didn’t get to all of them. And if you’re not in the Facebook group, that’s generally where I asked for questions for this kind of thing. It’s Diabetes Connections of the group. I’ll link it up in the show notes. As always, I know not everybody’s on Facebook, please feel free to always email me if you email me now about Dexcom. I’ll save those questions until the next time we talk to them. It’s Stacey at diabetes Again, it’s in the show notes and it’s on the website. But I get it not everybody is on Facebook these days.
To that point, at the very beginning of the show, in that little sponsor tease before things even begin, I mentioned club 1921. So let me tell you a little bit more might be an update for some of you. Maybe some of you are hearing about this for the very first time. Briefly, club 1921 is a website. It’s a project I’ve been working on for a long time. And it is a place where anyone with any type of diabetes can find events anywhere in the United States. We are in beta right now. I invite you to go to the website club 1920 Until around, check it out. Let me know what you think we’ve immediately identified we went into beta, late last fall several things mostly about the signup that need to be fixed, those could be fixed by the time you log in, my guess is closer to the end of January. There’s a little bit of confusion there. I’ll explain in a moment. But other than that, it’s pretty well set.
The idea here is that instead of a Google Calendar or something like that, this would be a website where you go, you sign up, you tell us what kind of events you’re looking for, and then you never have to come back, we’ll email you automatically. When events that meet your criteria are edit, very easy. So you pick your type of diabetes, you pick your location, you pick which type of events you want, you pick your age, I mean, you can just say I want everything in every category you can kind of go through, but whatever you pick, and you can change those if you want to come back and change your filters, but whatever you pick, we will email you when those events are added.
If you want to add events. There are two types of events you can add one we’re very creatively calling events. This is your JDRF walk. This is your friends for life conference. This is your hospital education for people with type two. It’s an event by an organization a was a staff an event where they expect lots of people or it’s regularly scheduled, or there’s a fee, that kind of thing. The other kind of events we’re calling Hangouts. These are my favorite types of events. I love what we’re calling Hangouts. This is your mom, coffee, your kid play date at a playground, you know, you’re going out to a bar, post COVID, with your adult friends with type one, hang outs are not put on by an established organization. They’re put on by people like you and me, we don’t have a staff, we just want to meet people in our area. When you’re adding those. That’s where a lot of the confusion came up in the registration process. Because if you want to add events or Hangouts, you actually have to sign up in a different way.
So I’m going to talk more about that as the weeks go on. We’re fixing that part of the website. But if you try to sign up and you see some confusion, it may be because you are trying to add an event or a Hangout. If you want to just sign up to learn about the events and Hangouts, it should be pretty simple. But if it’s not, if you have any questions, any suggestions, please let me know. Email me Stacey at diabetes Pretty soon you’ll email me Stacey at Club 1920 You’re going to be hearing a lot more about this because I’m so excited about it. Yes, I know, we might not have a lot of events this year, that’s fine. We’re going to have events, eventually, in the diabetes space. Again, we’re gonna have lots of events, and social media, Facebook, even things like Eventbrite are a terrible way to get the word out about them. And it shouldn’t be work to find them, you should be able to just raise your hand and say, I want to know about this stuff. And it should automatically come to you. And that’s what I’m hoping to do here.
Okay, back to our regular schedule with the podcast. We will have our Wednesday in the news that’s live at 430. Eastern on Wednesday on YouTube and Facebook, and then 445 on Instagram. And then that turns into an audio podcast episode for Fridays. And hopefully next week, we’re back to Tuesday and Friday. And we won’t do any of this nonsense of pushing episodes around. But I do appreciate your patience. Again, I didn’t want you to wait a week for this interview. All right, thank you as always to my editor, the very flexible and understanding John Bukenas from audio editing solutions. And thank you so much for listening. I’m Stacey Simms. I’ll see you back here in just a couple of days until then, be kind to yourself. Diabetes Connections is a production of Stacey Simms media. All rights reserved. All wrongs avenged

Find out more about Moms’ Night Out 

Please visit our Sponsors & Partners – they help make the show possible!

Learn more about Gvoke Glucagon Gvoke HypoPen® (glucagon injection): Glucagon Injection For Very Low Blood Sugar (

Omnipod – Simplify Life

Learn about Dexcom 

Edgepark Medical Supplies

Check out VIVI Cap to protect your insulin from extreme temperatures

Learn more about AG1 from Athletic Greens 

Drive research that matters through the T1D Exchange

The best way to keep up with Stacey and the show is by signing up for our weekly newsletter:

Sign up for our newsletter here

Here’s where to find us:

Facebook (Group)

Facebook (Page)



Check out Stacey’s books!

Learn more about everything at our home page 

Reach out with questions or comments: